Literature DB >> 22720231

Chemoimmunomodulation of MDSCs as a novel strategy for cancer therapy.

Julie Djeu1, Sheng Wei.   

Abstract

Tumor-induced myeloid-derived suppressor cells (MDSCs) are a critical barrier to effective immunotherapy of cancer. We identified that Docetaxel and a natural compound, Icariin, can target MDSCs with preferential apoptosis of M2 cells and polarization of the surviving cells towards M1 cells. Such strategic targeting of MDSCs restored T cell function accompanied by tumor retardation in vivo.

Entities:  

Year:  2012        PMID： 22720231      PMCID： PMC3376962          DOI： 10.4161/onci.1.1.18074

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.

Authors:  Kiavash Movahedi; Damya Laoui; Conny Gysemans; Martijn Baeten; Geert Stangé; Jan Van den Bossche; Matthias Mack; Daniel Pipeleers; Peter In't Veld; Patrick De Baetselier; Jo A Van Ginderachter
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

Review 2.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity.

Authors:  Alberto Mantovani; Antonio Sica
Journal:  Curr Opin Immunol       Date:  2010-02-09       Impact factor: 7.486

3.  A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.

Authors:  Krithika N Kodumudi; Karrune Woan; Danielle L Gilvary; Eva Sahakian; Sheng Wei; Julie Y Djeu
Journal:  Clin Cancer Res       Date:  2010-08-11       Impact factor: 12.531

4.  Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.

Authors:  Eiji Suzuki; Veena Kapoor; Arminder Singh Jassar; Larry R Kaiser; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

5.  Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions.

Authors:  Junmin Zhou; Jinfeng Wu; Xianghong Chen; Nicole Fortenbery; Erika Eksioglu; Krithika N Kodumudi; Epling-Burnette Pk; Jingcheng Dong; Julie Y Djeu; Sheng Wei
Journal:  Int Immunopharmacol       Date:  2011-01-15       Impact factor: 4.932

6.  Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.

Authors:  J D Veltman; M E H Lambers; M van Nimwegen; R W Hendriks; H C Hoogsteden; J P J J Hegmans; J G J V Aerts
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

7.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 8.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

9.  Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.

Authors:  Paolo Serafini; Kristen Meckel; Michael Kelso; Kimberly Noonan; Joseph Califano; Wayne Koch; Luigi Dolcetti; Vincenzo Bronte; Ivan Borrello
Journal:  J Exp Med       Date:  2006-11-13       Impact factor: 14.307

10.  Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein.

Authors:  Pingyan Cheng; Cesar A Corzo; Noreen Luetteke; Bin Yu; Srinivas Nagaraj; Marylin M Bui; Myrna Ortiz; Wolfgang Nacken; Clemens Sorg; Thomas Vogl; Johannes Roth; Dmitry I Gabrilovich
Journal:  J Exp Med       Date:  2008-09-22       Impact factor: 14.307
  10 in total
  4 in total

1.  Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents.

Authors:  Yichao Chen; Jingjing Sun; Yixian Huang; Binfeng Lu; Song Li
Journal:  Mol Pharm       Date:  2018-09-28       Impact factor: 4.939

Review 2.  Update on the challenges and recent advances in cancer immunotherapy.

Authors:  Gianfranco Baronzio; Gurdev Parmar; Irina Zh Shubina; Valter Cassutti; Sergio Giuli; Marco Ballerini; Mikhail Kiselevsky
Journal:  Immunotargets Ther       Date:  2013-06-15

3.  Plasmodium infection inhibits the expansion and activation of MDSCs and Tregs in the tumor microenvironment in a murine Lewis lung cancer model.

Authors:  Dickson Adah; Yijun Yang; Quan Liu; Kranthi Gadidasu; Zhu Tao; Songlin Yu; Linglin Dai; Xiaofen Li; Siting Zhao; Limei Qin; Li Qin; Xiaoping Chen
Journal:  Cell Commun Signal       Date:  2019-04-12       Impact factor: 5.712

Review 4.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.